Key Takeaways
- The Drug Regulatory Authority of Pakistan (DRAP) has banned counterfeit blood cancer medicines.
- Counterfeit batches of Darzalex and Jakavi have been identified, with samples detected in the Maldives and Mexico.
- Public and healthcare providers are advised to avoid these products due to potential life-threatening risks.
The Drug Regulatory Authority of Pakistan (DRAP) has issued a rapid warning against counterfeit blood cancer medicines following an alert from the World Health Organization (WHO). The affected batches include Darzalex injections and Jakavi tablets, both used in treating blood cancers. According to DRAP, these fake products have been identified through international surveillance efforts, with samples detected in the Maldives and Mexico.
Specifically, counterfeit batches of Darzalex 400 mg and 100 mg injections, as well as Jakavi 15 mg and 10 mg tablets, have been flagged. DRAP stated that these fake medicines failed testing standards due to unverifiable raw materials and the presence of foreign particles in one sample. The authority emphasized the potential life-threatening risks associated with using counterfeit medicines, highlighting their lack of safety and effectiveness guarantees.
In response, DRAP has banned the sale and use of the affected batches and urged the public and healthcare providers to avoid these products. The regulator also noted that it will continue monitoring the market for any further instances of falsified medicines. 'The use of counterfeit medicines can be life-threatening,' said an official from DRAP, stressing the importance of adhering to regulatory standards.
Healthcare professionals are advised to report any suspected cases of counterfeit medicines to the relevant authorities immediately. The public is also encouraged to verify the authenticity of their medications through authorized channels and avoid purchasing from unverified sources. 'We urge everyone to be vigilant,' said another official, adding that the ongoing collaboration between DRAP and international health organizations will help ensure the safety and efficacy of blood cancer treatments in Pakistan.
The alert underscores the global threat posed by counterfeit medicines, particularly those used for serious conditions such as blood cancers. The WHO has highlighted the importance of robust regulatory frameworks to combat this issue, with DRAP taking swift action to protect public health.
